MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
DALLAS, December 7, 2011 /PRNewswire/ –
The report “Acute Lymphocytic Leukemia Therapeutics Market (Pipeline Forecast & Market
Forecast in G8 Countries) (2010 – 2020)” analyzes and studies the major market drivers,
restraints, and opportunities in regions such as North America, & Europe.
Browse market data tables and in-depth TOC on Acute Lymphocytic Leukemia Therapeutics
Market (Pipeline Forecast & Market Forecast in G8 Countries) (2010 – 2020).
Early buyers will receive 10% customization on reports.
In acute lymphocytic leukemia, the body rapidly produces a large number of immature
white blood cells, called lymphocytes. These immature white blood cells replace normal
cells in the bone marrow. This type of cancer accounts for about 12% of the total
leukemia. This type of cancer can be sub-categorized into childhood acute lymphocytic
leukemia and adult acute lymphocytic leukemia.
Acute lymphocytic leukemia (ALL) is the most common type of leukemia in young
children. This disease also affects adults, especially those aged 65 and older. Standard
treatments involve chemotherapy and radiotherapy. The survival rates vary by age: 85% in
children and 50% in adults. Subtypes include precursor B acute lymphocytic leukemia,
precursor T acute lymphocytic leukemia, Burkitt leukemia, and acute biphenotypic leukemia.
The acute lymphocytic leukemia therapeutics market [
] was valued at $1.96 billion in 2010 and is expected to reach $3.88
billion by 2020, at a CAGR of 5.21% between 2015 and 2020. The market was dominated by
Hyper-CVAD regimen in 2010. However, in 2020, the market is expected to be equally
dominated by Hyper-CVAD and Linker regimen. The chemotherapy drug regimens were dominated
by Hyper-CVAD regimen sales, totaling $1.8 billion and linker regimen sales totaling $1.13
billion sales in acute lymphocytic leukemia market.
According to WHO, acute lymphocytic leukemia is expected to be more prominent in the
in more developed countries and higher socioeconomic groups such as North America and
European countries due to genetic factor. Other causes like environmental factor and
exposure to high doses of radiation are also the causative factors of all the types of
acute lymphocytic leukemia.
The U.S. dominates the North American leukemia drug market with a 90% share; whereas
Germany dominates the European market with 35% share.
Major players in the market include Ambit Biosciences Inc. (U.S.), ERYtech Pharma
(France), Talon Therapeutic Inc. (U.S.), and Genzyme Corporation. (U.S.).
MarketsandMarkets is a global market research and consulting company based in the U.S.
We publish strategically analyzed market research reports and serve as a business
intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and
custom research services. MarketsandMarkets covers thirteen industry verticals; including
advanced materials, automotives and transportation, banking and financial services,
biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial
automation, medical, pharmaceuticals [
semiconductor and electronics, and telecommunications and IT.
We at MarketsandMarkets are inspired to help our clients grow by providing apt
business insight with our huge market intelligence repository. To know more about us and
our reports, please visit our website http://www.marketsandmarkets.com.
Contact: Mr. Rohan 7557 Rambler Road, Suite 727, Dallas, TX 75231 Tel: +1-888-6006-441 Email: email@example.com MarketsandMarkets Blog @ http://www.marketsandmarketsblog.com http://www.sandlerresearch.org http://twitter.com/marketsmarkets